Skip Navigation


Carcinogenesis Advance Access originally published online on September 24, 2007
Carcinogenesis 2008 29(1):169-176; doi:10.1093/carcin/bgm209
This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow All Versions of this Article:
29/1/169    most recent
bgm209v1
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in ISI Web of Science
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Add to My Personal Archive
Right arrow Download to citation manager
Right arrow Search for citing articles in:
ISI Web of Science (2)
Right arrowRequest Permissions
Google Scholar
Right arrow Articles by Hollingshead, H. E.
Right arrow Articles by Peters, J. M.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Hollingshead, H. E.
Right arrow Articles by Peters, J. M.
Social Bookmarking
Add to CiteULike   Add to Connotea   Add to Del.icio.us  
What's this?

© The Author 2007. Published by Oxford University Press. All rights reserved. For Permissions, please email: journals.permissions@oxfordjournals.org

Ligand activation of peroxisome proliferator-activated receptor-β/{delta} (PPARβ/{delta}) and inhibition of cyclooxygenase 2 (COX2) attenuate colon carcinogenesis through independent signaling mechanisms

Holly E. Hollingshead1,2, Michael G. Borland1,2, Andrew N. Billin3, Timothy M. Willson3, Frank J. Gonzalez4 and Jeffrey M. Peters1,2,*

1 Department of Veterinary and Biomedical Sciences and The Center of Molecular Toxicology and Carcinogenesis
2 Graduate Program in Biochemistry, Microbiology, and Molecular Biology, The Pennsylvania State University, University Park, PA 16802, USA
3 Nuclear Receptor Discovery Research, GlaxoSmithKline, Research Triangle Park, NC 27709, USA
4 Laboratory of Metabolism, National Cancer Institute, Bethesda, MD 20892, USA

* To whom correspondence should be addressed. Tel: +1 814 863 1387; Fax: +1 814 863 1696; Email: jmp21{at}psu.edu

Cyclooxygenase (COX) 2-derived prostaglandin E2 (PGE2) promotes colorectal carcinoma growth and invasion, and inhibition of COX2 by non-steroidal anti-inflammatory drugs is known to inhibit these processes. There is controversy regarding the effect of ligand activation of peroxisome proliferator-activated receptor (PPAR)-β/{delta} on colon carcinogenesis, although collective evidence from independent laboratories suggest that ligand activation of PPARβ/{delta} leads to the induction of terminal differentiation coupled with inhibition of cell growth in a variety of models. The present study examined the hypothesis that ligand activation of PPARβ/{delta} and inhibition of COX2 attenuate colon cancer through independent mechanisms and that combining these two mechanisms will enhance this inhibition. Colon cancer was induced by administering azoxymethane to wild-type and PPARβ/{delta}-null mice. Cohorts of mice were treated with GW0742 (a PPARβ/{delta} ligand), nimesulide (a COX2 inhibitor) or a combination of GW0742 and nimesulide. Inhibition of COX2 by nimesulide attenuated colon cancer and ligand activation of PPARβ/{delta} by GW0742 had inhibitory effects. However, the combined treatment of GW0742 and nimesulide did not cause an enhancement in the attenuation of colon cancer. Mechanistically, the effects of these compounds occurred through independent mechanisms as increased levels of differentiation markers as a result of ligand activation of PPARβ/{delta} were not found with COX2 inhibition, and a reduction in PGE2 levels resulting from COX2 inhibition was not observed in response to ligand activation of PPARβ/{delta}. Results from these studies effectively dissociate COX2 inhibition and PPARβ/{delta} activity during colon carcinogenesis.

Abbreviations: APC, adenomatous polyposis coli; ADRP, adipocyte differentiation-related protein; ANGPTL4, angiogenin-related protein-like 4; AOM, azoxymethane; BrdU, bromodeoxyuridine; COX, cyclooxygenase; CRC, colorectal cancer; mRNA, messenger RNA; NSAID, non-steroidal anti-inflammatory drugs; PCR, polymerase chain reaction; PGE2, prostaglandin E2; PPAR, peroxisome proliferator-activated receptor

Received June 8, 2007; revised August 29, 2007; accepted September 12, 2007.


Add to CiteULike CiteULike   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us    What's this?


This article has been cited by other articles:


Home page
 Toxicol SciHome page
W. Shan, P. S. Palkar, I. A. Murray, E. I. McDevitt, M. J. Kennett, B. H. Kang, H. C. Isom, G. H. Perdew, F. J. Gonzalez, and J. M. Peters
Ligand Activation of Peroxisome Proliferator-Activated Receptor {beta}/{delta} (PPAR{beta}/{delta}) Attenuates Carbon Tetrachloride Hepatotoxicity by Downregulating Proinflammatory Gene Expression
Toxicol. Sci., October 1, 2008; 105(2): 418 - 428.
[Abstract] [Full Text] [PDF]


Disclaimer:
Please note that abstracts for content published before 1996 were created through digital scanning and may therefore not exactly replicate the text of the original print issues. All efforts have been made to ensure accuracy, but the Publisher will not be held responsible for any remaining inaccuracies. If you require any further clarification, please contact our Customer Services Department.